Introduction
Hemophilia A (Hem-A) is a common bleeding disorder characterized by a deficiency in blood coagulation factor VIII (FVIII). Intravenous administration of plasma-derived or recombinant FVIII protein is currently the most widely accepted treatment for bleeding episodes in this patient population. However, in severe hemophilic patients (<1% FVIII), spontaneous bleeds into muscles and joints occur frequently causing progressive debilitation. Studies have shown that prophylactic infusion of FVIII protein, sufficient to maintain levels greater than 1% prevents chronic arthropathy in patients 1 . However, high costs and difficulties associated with accessing peripheral veins have prevented the widespread implementation of primary prophylactic treatments in the United States.
Protein replacement therapy is also complicated by the fact that approximately 20% of severe hemophilic patients develop inhibitory antibodies to FVIII 2 .
Gene therapy could provide an attractive alternative to current therapies by maintaining continuous expression of FVIII at levels above 1% of normal. Encouraging data has been generated in normal and hemophilic mice using retroviral and adenoviral vectors 3 4 5 . Using a third generation E1/ E2A/ E3 deleted adenoviral vector, sustained expression of canine FVIII (cFVIII) was achieved in Hem-A mice 6 ; however, subsequent studies in dogs resulted in short term expression, inhibitor development and liver toxicity 7 . Balague et al., (2000) 5 using a gutted adenovirus, demonstrated sustained FVIII expression and phenotypic correction in Hem-A mice. However, in the follow up clinical trial, liver toxicity was observed in the single subject that was treated at a low dose. Only one clinical trial using a non-viral approach has reported significant levels of FVIII expression 8 . In this trial, autologous fibroblasts were transplanted into patients only.
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FVIII levels of up to 4% were seen in one patient; however, expression was transient and disappeared by one year post-implantation.
Adeno-associated viral (AAV) vectors have been demonstrated to provide sustained transgene expression without toxicity in mice, rats, dogs, and non-human primates 9 10 . In hemophilia B gene therapy studies, intra-hepatic injections of AAVFactor IX (FIX) vectors in dogs resulted in sustained expression of FIX above 1% of normal 11, 12 . No toxicity or inhibitor development was seen in a phase I clinical trial when an AAV-hFIX vector was delivered intramuscularly to hemophilia B patients 13 14 .
However, in another Phase I clinical trial intra-hepatic artery delivery of an AAV -FIX vector resulted in transient elevations in transaminases in one subject 15 . Therefore, the toxicity of this vector in humans awaits further clinical evaluation.
Delivery of the FVIII gene using AAV vectors has been limited by its small packaging capacity (4.7-kb). One strategy, currently under investigation, involves using minimal regulatory sequences to drive expression of a B-domain -deleted form of FVIII 16 (Jiang et al., manuscript in preparation). An alternative approach, which permits the use of larger regulatory elements, utilizes two AAV vectors to deliver the heavy chain (HC) and light chain (LC) of FVIII separately. This approach exploits the fact that FVIII is normally expressed as a large single chain polypeptide of 280 kDa with a domain structure: A1-A2-B-A3-C1-C2 2 . Upon secretion, the B-domain is proteolytically cleaved to generate the HC and LC polypeptides. A number of groups have demonstrated that cotransfection of Chinese hamster ovary (CHO) cells with plasmids encoding the FVIII-HC and FVIII-LC reconstitutes FVIII activit y in vitro 17 18 . We previously demonstrated that only.
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Materials and Methods

Vector Construction, Production and Purification
The AAV-hFVIII-HC, the AAV-hFVIII-LC, the AAV-cFVIII-HC and the AAV-cFVIII-LC constructs have identical regulatory sequences, which include the apolipoprotein E hepatic control region, the human alpha one anti-trypsin promoter, a CMV/ -globin chimeric intron, and a human growth hormone polyadenylation sequence 20 . Each construct also contains the first 57-bp of either the human or canine FVIII-HC, which encodes the 19 amino acid (aa) signal sequence. The AAV-hFVIII-HC construct encodes the A1 and A2 domain and 5 aa (residues 741-745) from the amino terminus of the Bdomain. The AAV-cFVIII-HC construct contains the corresponding canine sequences except the A1-A2 domain is followed by the sequence encoding 89 aa (residues 734-822) from the amino terminus of the canine B-domain. The human and canine FVIII-LC constructs contain the sequence corresponding to 86 aa (human residues, 1563-1648;
canine residues, 1555-1640) of the carboxy terminal B-domain plus the entire A3-C1-C2
domains of the LC. The hFVIII-HC and hFVIII -LC sequences were derived from AAV-EF1 -hFVIII-HC and AAV-EF1 -hFVIII-LC respectively 19 . The canine HC and LC cDNA sequences were derived by reverse transcription of canine RNA purified from normal canine liver using the method of Chomczynski and Sacchi (1987) 21 . Cloning of the canine sequences is described by Sarkar et al. (manuscript in preparation).
AAV vectors were produced using a triple transfection method 22 and purified by column chromatography 23 . Vector genomes (vg) were quantified using Quantitative Real
Time PCR (Q-PCR) with primers and probes specific for human or canine FVIII-HC and LC and using linerized plasmid DNA as a standard. 
FVIII Assays
The concentration of hFVIII-HC and LC antigen was determined using chain specific For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From PhosphoImager (Molecular Devices, Sunnyvale, CA) and the copy numbers determined using IMAGEQUANT SOFTWARE (Molecular Devices, Sunnyvale, CA).
For the cFVIII-HC or LC copy number determinations, 10 µg of genomic DNA was digested with EcoRI, separated on a 1% gel and hybridized with a 32 P-labeled 1707-bp EcoRI fragment from cFVIII-HC or a 32 P-labeled 1214-bp BglII/ EcoRI cFVIII-LC fragment.
RNA copies were determined by RT-QPCR using 10 ng of total RNA. The standards used were in vitro transcribed single chain human and canine FVIII RNAs.
Primers and probes to both the human and canine, HC and LC sequences were used. The 
RNA FISH Analysis of canine FVIII
RNA in situ hybridization was performed as described 28 . In brief, liver tissue was harvested and mounted in Optimal Cutting Temperature Compound (Sakura Finetek USA, Inc., Torance, CA). Twelve µm sections were generated using a cryostat and fixed in 4% formaldehyde/ PBS. After washing with PBS and 2 X SSC, the sections were treated with 3% H 2 O 2 at room temperature for 20 minutes. Sections were then washed in nuclease free H 2 O, and dehydrated sequentially in 70%, 95% and 100% ethanol. The only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From following HRP conjugated canine chain specific anti-sense probes were designed: cFVIII-HC probe (5'GAGCTGTCGTCATCAAAGCTAACT ACGTCC 3'); cFVIII-LC probe cocktail (Probe 1: 5'GAGGCCCTGATTTTCATAGTC GCCGTAGAT3'; Probe 2:
5'ATTGCAGGGAGCTCTACA GTTCCTTTCCAG3') (Epoch Biosciences, Bothell, WA). Sections were first hybridized with the cFVIII-HC probe, and the hybrids were detected as a green signal with TSA-FITC (Perkin Elmer, Boston, MA). A consecutive hybridization was performed on the same sections with the cFVIII-LC probe, and the hybridization signal was detected as a red signal using TSA-Alexa 554 (Molecular Probes, Inc., Eugene, OR). Sections were mounted in Prolong TM anti-fade (Molecular Probes, Inc., Eugene, Oregon), and examined using a Zeiss Axioskop fluorescence microscope (Carl Zeiss, Thornwood, NY). Images were recorded using a Quips imaging system and software (Applied Imaging, Santa Clara, CA). The transduction efficiency was determined after counting at least 2,000 nuclei per section.
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Results
In Vitro Production of Biologically Active FVIII
Previously we demonstrated that biologically active hFVIII can be produced following co-injection of normal mouse liver with hFVIII-HC and LC vectors utilizing a ubiquitous promoter 19 . In the present study, we further optimized this approach by designing AAV human and canine FVIII-HC and LC vectors that utilize liver specific regulatory elements (the apolipoprotein E hepatic control region (HCR) and the human alpha one anti-trypsin (hATT) promoter) ( Figure 1 ), and evaluated these vectors in the Hem-A mouse model.
These liver specific elements allowed high levels of FIX expression in vivo 20 . The FVIII constructs were evaluated for FVIII activity following transduction of HepG2 cells.
When the HC or LC vectors were used alone, no FVIII activity was detected ( To test the efficacy of this approach in vivo we co -injected vectors encoding the canine heavy and light chains of FVIII into the portal veins of Hem-A mice. Three groups of six animals were injected with increasing doses of AAV-cFVIII-HC and AAV-cFVIII-LC vectors at a 1:1 ratio (3x10 10 , 3x10 11 or 9x10 11 vg /mouse). FVIII activity and FVIII-LC antigen levels were measured at various time points. Prior to these experiments, we determined, using the Coatest and hFVIII as a standard, that the normal activity of cFVIII is 7000 mU/mL. We also determined using a hFVIII-LC ELISA that cross reacts with cFVIII, and hFVIII as a standard, that the normal FVIII-LC antigen level in canine plasma is 200 ng/mL. Therefore, unlike hFVIII, which has a specific activity of 5,000 U/mg, the specific activity of cFVIII is 35,000 U/mg relative to a hFVIII standard.
Super-physiological levels of cFVIII-LC antigen and FVIII activity were generated in animals injected with the two highest vector doses (Figure 2A & B) .
For example, at the 12 week time point animals injected with 3x10 11 vg secreted an average of 8,952 ng/mL of cFVIII-LC antigen, resulting in FVIII activity levels of only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From 15,854 mU/mL. At this same time point, the 3x10 10 vg group had considerably lower levels of both antigen and activity (622 ng/mL, 454 mU/mL), but these activity levels (6.5%) were still in the therapeutic range; i.e. > 1% of normal cFVIII levels. At all doses, more FVIII-LC antigen was observed in the plasma than would have been expected based on the FVIII activity, suggesting that the specific activity of the protein is lower than normal. However, given the absence of a cFVIII-HC ELISA, the specific activity for the expressed cFVIII was based only on the circulating LC levels. Following administration of 3x10 11 vg/mouse, FVIII specific activity measurements ranged from 900-6000 U/mg ( Figure 2C ), which is lower than that of normal canine plasma (35,000 U/mg).
High levels of both FVIII antigen and activity were sustained for over 30 weeks post-vector injection, although a decrease from peak levels was observed. This decrease in expression was associated with the development of inhibitory antibodies (1-5 BU) in some animals (6/8 mice) (data not shown). To determine whether these levels of cFVIII could correct the bleeding phenotype in the animals, we performed a tail clip survival assay 12 weeks post-injection. All the mice in the treated groups survived the tail clipping, whereas no mice in the control group survived (Table 2 ). These data demonstrate that biologically active FVIII can be produced in vivo following delivery of two AAV vectors encoding the heavy and light chains of cFVIII, resulting in correction of the bleeding phenotype.
For Among the animals injected with both vectors, FVIII activity ranged between <5% (50 mU/mL) and 55.9 % (559 mU/mL) of normal, with four out of six animals having levels above 50 mU/mL, the sensitivity of the assay (Table 3) . These levels are lower than those seen when Hem-A animals were injected with the cFVIII constructs. We believe the reason for this is two fold. The first is that the specific activity of cFVIII is seven fold higher than hFVIII, and secondly we have previously observed up to five fold lower only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From levels of expression in animals with the Rag1 phenotype compared to immunocompetent animals (unpublished data). ELISA analysis of plasma from co-injected animals demonstrated considerably higher levels (average of 25-100 fold) of hFVIII-LC antigen compared to hFVIII-HC antigen ( Figure 3A ). This discrepancy between FVIII-HC and LC expression was also observed by comparing the plasma levels achieved in animals injected with a single vector ( Figure   3B ,C). Using the hFVIII-LC antigen to determine the specific activity we calculate values up to 348 U/mg (7% of normal). In contrast, when the hFVIII-HC antigen was used to calculate the specific activity, values up to 6969 U/mg (139% of normal) were determined.
only. For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From not associated with HC. However, the HC that is secreted appears to be complexed with the LC. When EDTA was included in the immunoprecipitations, the dissociated HC and LC peptides were precipitated at levels similar to that seen in the absence of EDTA ( Figure 4A, lanes 4 and 5) . These data demonstrate that following co-injection of AAVhFVIII-HC and AAV-hFVIII-LC vectors, the HC and LC peptides are properly processed and associated, however, a large excess of inactive, non-complexed LC antigen is produced.
Biochemical analysis of intracellular hFVIII in vivo
To further evaluate the low levels of hFVIII-HC, we analyzed liver lysates from animals For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From both forms of the LC ( Figure 4B, lanes 9 and 10) , while animals injected with the HC vector alone produced a 90 kDa HC polypeptide in the liver ( Figure 4B, lanes 11 and 12) .
The combined data demonstrate that the non-stoichiometric levels of FVIII-HC and LC observed in the plasma of co-injected animals correlates with lower intracellular levels of the FVIII-HC.
Molecular analysis of vector DNA and RNA in vivo
In order to determine if differential gene transfer could account for the differences in HC and LC protein in liver lysates, the copy numbers of the hFVIII-HC and hFVIII-LC transgenes in the co-injected Hem-A/ Rag1 mice were determined by Southern blot analysis. Mice injected at a dose of 3x10 11 vg of each vector were euthanized eighteen weeks post-injection, and DNA was extracted from the liver. The copy number of the only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From hFVIII-HC transgene in four co-injected animals was greater than that of the hFVIII-LC transgene by 1.6-4 fold ( Figure 5A and B) .
RNA levels were also evaluated using quantitative RT-PCR analysis. When normalized for gene copy, similar levels of hFVIII-HC and hFVIII-LC RNA were observed ( Figure 5A and B) . Thus, the lower levels of hFVIII-HC protein are not due to less efficient gene transfer or lower steady state levels of RNA transcripts.
Gene transfer and RNA expression was also analyzed in Hem-A mice that were injected with the canine vectors at a dose of 3x10 11 The quantitative data presented here was obtained by analysis of multiple sections from a single animal, which had similar copy numbers of the two transgenes. Using an anti-sense probe specific for the HC, we observed approximately 42% positive hepatocytes ( Figure 6A ). When the anti-sense LC specific oligonucleotide was used, 18% of cells were positive ( Figure 6B ). This difference in staining between the HC and LC signal was demonstrated to be due to differences in sensitivity between the two probes (data not shown). When liver sections were hybridized with both probes, 47% of the cells stained positive for HC and/ or LC RNA ( Figure 6C ) and co-transduction was determined in 12% of total hepatocytes, or 26% of all transduced hepatocytes. No signal was seen in sections from naïve mice hybridized with the anti-sense probes ( Figure 6D ).
Similarly, no signal was seen in livers from injected mice hybridized with the sense probes, or pretreated with RNAse and hybridized with the anti-sense probes (data not shown), confirming that the signal was due to RNA. 
Discussion
Previously we demonstrated in normal mice that co-injection of AAV vectors encoding the HC and LC of FVIII resulted in the secretion of biologically active FVIII 19 . In this study, we made use of the Hem-A mouse model to confirm and extend our earlier observations. Following co-injection of Hem-A mice with liver specific AAV-cFVIII HC and LC vectors at a dose of 3x10 11 vg/mouse, peak plasma LC antigen levels up to 10,560 ng/mL were observed 12 weeks post-injection, and activity levels in excess of 200% of normal were seen. Using the cFVIII-LC antigen levels detected using a LC ELISA and the activity levels determined using the Coatest assay to calculate the specific activity, we find that the specific activity of cFVIII in the plasma of co-injected animals is considerably lower than normal, which we have calculated to be 35,000 U/mg. In this study, the specific activity of cFVIII ranged from 870-5,779 U/mg (2.4-16.5% normal),
implying that a large excess of inactive protein is secreted. When AAV-hFVIII-HC and LC vectors were co-injected into Hem-A/ Rag1 mice, therapeutic levels of FVIII were achieved (up to 60% of normal at six weeks). However, chain specific ELISAs demonstrated that 25-100 fold more FVIII-LC was produced compared to FVIII-HC.
When the LC antigen was used to calculate the specific activity, the expressed hFVIII had a lower than normal value (up to 7% of normal). In contrast, when the hFVIII-HC was used to calculate the specific activity near normal levels (up to 139% of normal)
were determined. These data suggest that the active FVIII complex formed using this approach has a specific activity similar to that of normal hFVIII. Presumably, this chain imbalance also exists for the cFVIII.
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There are a number of reasons that could account for this chain imbalance, including differences in vector gene transfer, transgene transcription, and/ or protein translation and secretion. Using biochemical techniques designed for hFVIII, we demonstrated that posttranscriptional events contribute to the chain imbalance observed. A sensitive immunoprecipitation technique demonstrated that hFVIII heavy and light chains of the expected size are secreted into the blood stream of Hem-A mice and that these chains associate in a metal ion-dependent manner, as has been noted for wild-type FVIII.
However, unlike wild-type FVIII, the chains are found in a non-stoichiometric ratio, with an excess of LC when compared to HC as determined by chain specific ELISAs. This chain imbalance also appears to exist intracellularly, suggesting that the difference in plasma levels is not simply due to enhanced secretion or plasma stability of the LC. ApoE-HCR, Apolipoprotein E Hepatic Control Region, hAAT, human alpha one antitrypsin promoter; intron, CMV--globin chimeric intron; hGH PA, human growth hormone poly A. The human heavy chain is composed of the A1 and A2 domains preceded by the FVIII signal sequence, SS. The hFVIII-HC is followed by 5 aa (741-745) of the B-domain. The cFVIII-HC construct is identical except in addition to the above elements in the human construct, the cFVIII-HC construct is followed by 89 aa of the upstream B-domain (734-822). The human and canine light chain constructs are preceded by 86 aa of the B-domain, then the A3, C1 and C2 regions. Table 1 . FVIII expression in vitro. HepG2 cells were infected with each vector at a dose of 1x10 4 vg / cell. The following vectors were tested: AAV-hFVIII-HC, AAV-hFVIII-LC, both AAV-hFVIII-HC and AAV-hFVIII-LC, AAV-cFVIII-HC, AAV-cFVIII-LC, and both AAV-cFVIII-HC and AAV-cFVIII-LC, or with no vector. Forty-eight hours post-infection, the media was harvested and analyzed for LC antigen expression using a hFVIII-LC ELISA that cross reacts with cFVIII. The hFVIII-HC ELISA is only specific for hFVIII-HC. FVIII activity was determined by the Coatest assay. All wells were transduced in duplicate and assayed in quadruplet. (triangles) vg/ mouse of both AAV-cFVIII-HC and AAV-cFVIII-LC. Mice were bled periodically via the retro-orbital plexus, plasma was harvested and analyzed by ELISA for cFVIII-LC antigen expression (Figure 2A ) and by Coatest for FVIII activity ( Figure 2B ). The specific activity was calculated based on the determined activity and LC antigen levels ( Figure 2C ). In normal cFVIII plasma the antigen and activity levels are 200 ng/mL and 7000 mU/mL respectively. Table 2 . Phenotypic correction of hemophilia A mice. Hem-A mice were injected with AAV-cFVIII-HC and AAV-cFVIII-LC vectors. Twelve weeks post-injection the mice were lightly anesthetized with isoflurane and their tails were clipped at an internal diameter of 2.0 mm. Mice were monitored for survival over a 24 hour period. Activity levels at time of clipping are shown. Table 3 . Efficacy of AAV-hFVIII vectors in vivo at six weeks post injection. Hem-A/Rag1 mice were injected with 3x10 11 vg/mouse of both AAV-hFVIII-HC and AAVhFVIII-LC or AAV-hFVIII-LC alone or AAV-hFVIII-HC alone. FVIII-LC and HC antigen levels were determined by antigen specific ELISAs. FVIII activity was determined by Coatest. Specific activity levels based on both the heavy and light chains were separately determined. 11 vg/mouse of both AAV-hFVIII-HC and AAV-hFVIII-LC ( Figure 3A) , AAV-hFVIII-LC ( Figure 3B ) and AAV-hFVIII-HC ( Figure 3C ). Mice were bled periodically, plasma harvested and FVIII heavy (squares) and light chain antigen levels (diamonds) were measured by chain specific ELISA's. 11 vg AAV-hFVIII-HC and AAV-hFVIII-LC (samples 1.1, 1.2, 2.0, 2.1, 2.2, 3.0), AAVhFVIII-LC (sample 3.2) or AAV-hFVIII-HC (sample 4.2). For the hFVIII-HC copy number determination, the DNA (10 µg) was digested with Hind III (Fig. 5A) , while for the light chain copy number the DNA was digested with Pst I (Fig. 5B) .
32 P-random primer labeled heavy and light chain probes were used for the respective blots. Heavy and light chain RNA levels were determined by RT-QPCR using heavy and light chain specific primers and probes. The DNA copy numbers are expressed as copies per diploid genome. The RNA levels are expressed as copies/ 10 ng RNA and have been normalized to 1 DNA copy/ cell by dividing by the DNA copy number that was determined by Southern blot analysis. Figure 6A-D) . Sections were probed sequentially with a heavy chain specific probe (green; Figure 6A ) and then with a cocktail of two light chain specific probes (red; Figure 6B ). Co-localization of both transcripts is indicated by the yellow staining (yellow; Figure 6C ). No signal was seen in sections from untreated mice ( Figure 6D 
